{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:02:05Z","timestamp":1794668525750,"version":"4.9.1"},"reference-count":100,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (HCT) is essential for treatment planning; however, the parameters that define an \u201coptimal\u201d donor in the modern era are not well defined. Historically, donor-recipient HLA mismatching correlated strongly with risk for graft-versus-host disease (GVHD) and reduced survival. For this reason, donor selection was typically hierarchical: HLA-matched related and unrelated donors were evaluated first, followed by HLA-mismatched donors (or deferral of HCT altogether) in patients lacking an HLA-matched donor. The advent of posttransplant cyclophosphamide (PTCy)-based GVHD prevention has changed this paradigm. Survival outcomes after HLA-mismatched donor HCT with PTCy, including from related haploidentical or HLA-mismatched unrelated donors, approach those in HLA-matched donor recipients in recent clinical trials and retrospective studies. These encouraging results present a new challenge: In the PTCy era, how should donors be prioritized among the many potential sources available? Herein, we review HLA and non-HLA parameters that inform adult donor selection, address disease-specific considerations, and discuss approaches to increase donor availability, including use of match probability-based donor search. Case vignettes focusing on concepts that may be adapted to heterogeneous clinical scenarios are presented.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030823","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:18:16Z","timestamp":1772126296000},"page":"1903-1913","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide"],"prefix":"10.1182","volume":"147","author":[{"given":"Brian C.","family":"Shaffer","sequence":"first","affiliation":[{"name":"1Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical School, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2600-6390","authenticated-orcid":false,"given":"Stephanie J.","family":"Lee","sequence":"additional","affiliation":[{"name":"3Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"1Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical School, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2026042311214051600_bib1","doi-asserted-by":"crossref","first-page":"e179944","DOI":"10.1172\/JCI179944","article-title":"Major breakthroughs in hematopoietic stem cell transplantation and future challenges in clinical implementation","volume":"134","author":"Kean","year":"2024","journal-title":"J Clin Invest"},{"issue":"4","key":"2026042311214051600_bib2","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.1999.17.4.1234","article-title":"Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies","volume":"17","author":"Porter","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026042311214051600_bib3","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.1997.15.5.1767","article-title":"Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings","volume":"15","author":"Szydlo","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026042311214051600_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0955-3886(94)90134-1","article-title":"Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors","volume":"15","author":"Anasetti","year":"1994","journal-title":"Transfus Sci"},{"issue":"3","key":"2026042311214051600_bib5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2015.09.012","article-title":"On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source","volume":"22","author":"Besse","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2026042311214051600_bib6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2026042311214051600_bib7","first-page":"686.e1-686.e8","article-title":"Existence of HLA-mismatched unrelated donors closes the gap in donor availability regardless of recipient ancestry","volume":"29","author":"Chowdhury","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2026042311214051600_bib8","first-page":"244","article-title":"Unrelated stem cell donor HLA match likelihood in the US registry incorporating HLA-DPB1 permissive mismatching","volume":"29","author":"Gragert","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"13","key":"2026042311214051600_bib9","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2026042311214051600_bib10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bbmt.2010.09.012","article-title":"HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation","volume":"17","author":"Woolfrey","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"17","key":"2026042311214051600_bib11","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1182\/blood-2011-09-381699","article-title":"Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia","volume":"119","author":"Saber","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2026042311214051600_bib12","first-page":"505","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy - a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"2026042311214051600_bib13","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"key":"2026042311214051600_bib14","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.25.25322901","article-title":"Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant","author":"Siegel","year":"26  2025","journal-title":"medRxiv"},{"key":"2026042311214051600_bib15","first-page":"327","article-title":"A comparison of the effects of selected cytotoxic agents on allogeneic skin graft survival in rats","volume":"116","author":"Santos","year":"1965","journal-title":"Bull Johns Hopkins Hosp"},{"issue":"2","key":"2026042311214051600_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026042311214051600_bib17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2026042311214051600_bib18","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with post-transplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"25","key":"2026042311214051600_bib19","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"28","key":"2026042311214051600_bib20","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.24.00184","article-title":"Post-transplant cyclophosphamide\u2013based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors","volume":"42","author":"Shaffer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026042311214051600_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"key":"2026042311214051600_bib22","author":"Devine","year":"30  2025"},{"issue":"3","key":"2026042311214051600_bib77","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2026042311214051600_bib75","first-page":"680","article-title":"Choosing between HLA-mismatched unrelated and haploidentical donors: donor age considerations","volume":"31","author":"Mehta","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"11","key":"2026042311214051600_bib91","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s41409-024-02400-5","article-title":"Young (&lt;35 years) haploidentical versus old (\u226535 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"59","author":"Nagler","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2026042311214051600_bib74","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/bloodadvances.2025017194","article-title":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using post-transplant cyclophosphamide","volume":"10","author":"Modi","year":"2025","journal-title":"Blood Adv"},{"issue":"26","key":"2026042311214051600_bib92","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research Analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026042311214051600_bib93","first-page":"184.e1-184.e9","article-title":"Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas","volume":"29","author":"Mussetti","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2026042311214051600_bib81","first-page":"208.e1-208.e6","article-title":"Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplant cyclophosphamide: follow-up from a National Marrow Donor Program-sponsored prospective clinical trial","volume":"29","author":"Shaw","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"18","key":"2026042311214051600_bib94","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"2026042311214051600_bib51","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO-25-00856","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation","volume":"43","author":"Al","year":"2025","journal-title":"J Clin Oncol"},{"issue":"28","key":"2026042311214051600_bib69","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1200\/JCO.24.00582","article-title":"Human leukocyte antigen mismatching and survival in contemporary hematopoietic cell transplantation for hematologic malignancies","volume":"42","author":"Arrieta-Bola\u00f1os","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026042311214051600_bib40","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood.2023023697","article-title":"Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT","volume":"143","author":"Sanz","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026042311214051600_bib41","first-page":"981","article-title":"Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"111","author":"Sanz","year":"2025","journal-title":"Haematologica"},{"issue":"12","key":"2026042311214051600_bib95","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/ajh.27466","article-title":"Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"99","author":"Baron","year":"2024","journal-title":"Am J Hematol"},{"issue":"11","key":"2026042311214051600_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood.V112.11.561.561","article-title":"The clinical significance of matching for alleles at the low expression HLA loci DP, DQ and DRB3\/4\/5 in unrelated hematopoietic stem cell transplantation","volume":"112","author":"Fernandez-Vina","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2026042311214051600_bib24","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1200\/JCO.23.01264","article-title":"HLA haplotypes and relapse after hematopoietic cell transplantation","volume":"42","author":"Petersdorf","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026042311214051600_bib25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(12)70004-9","article-title":"Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study","volume":"13","author":"Fleischhauer","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026042311214051600_bib26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1500140","article-title":"High HLA-DP expression and graft-versus-host disease","volume":"373","author":"Petersdorf","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2026042311214051600_bib27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2020008464","article-title":"Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM","volume":"137","author":"Meurer","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2026042311214051600_bib28","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.22.01229","article-title":"Impact of the HLA immunopeptidome on survival of leukemia patients after unrelated donor transplantation","volume":"41","author":"Crivello","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026042311214051600_bib29","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2024-200386","article-title":"Immunopeptidome divergence between mismatched HLA haplotypes and survival after haploidentical HCT: a retrospective study from the CIBMTR [abstract]","volume":"144","author":"Crivello","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026042311214051600_bib30","first-page":"74.e1-74.e14","article-title":"Post-transplant cyclophosphamide improves survival in HLA-DPB1 mismatched unrelated donor allogeneic transplantation","volume":"32","author":"McCurdy","year":"2026","journal-title":"Transpl Cell Ther"},{"issue":"14","key":"2026042311214051600_bib31","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/bloodadvances.2024014858","article-title":"Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis","volume":"9","author":"Nath","year":"2025","journal-title":"Blood Adv"},{"issue":"10","key":"2026042311214051600_bib32","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.2021013443","article-title":"HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide","volume":"139","author":"Fuchs","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2026042311214051600_bib33","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2009-09-244525","article-title":"The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure","volume":"115","author":"Spellman","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2026042311214051600_bib34","doi-asserted-by":"crossref","first-page":"eaag1672","DOI":"10.1126\/sciimmunol.aag1672","article-title":"Class I HLA haplotypes form two schools that educate NK cells in different ways","volume":"1","author":"Horowitz","year":"2016","journal-title":"Sci Immunol"},{"issue":"7","key":"2026042311214051600_bib35","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41590-023-01523-z","article-title":"HLA class I signal peptide polymorphism determines the level of CD94\/NKG2\u2013HLA-E-mediated regulation of effector cell responses","volume":"24","author":"Lin","year":"2023","journal-title":"Nat Immunol"},{"issue":"5","key":"2026042311214051600_bib36","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2026042311214051600_bib37","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","article-title":"The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy","volume":"127","author":"Kollman","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2026042311214051600_bib38","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1182\/bloodadvances.2024013756","article-title":"Novel machine learning technique further clarifies unrelated donor selection to optimize transplantation outcomes","volume":"8","author":"Spellman","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026042311214051600_bib39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3324\/haematol.2018.215202","article-title":"Alternative donor transplantation for acute myeloid leukemia in patients aged \u226550 years: young HLA-matched unrelated or haploidentical donor?","volume":"105","author":"Perales","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"2026042311214051600_bib96","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3324\/haematol.2020.264424","article-title":"Use of the HLA-B leader to optimize cord blood transplantation","volume":"106","author":"Petersdorf","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"2026042311214051600_bib97","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41375-024-02256-0","article-title":"Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis","volume":"38","author":"Ramdial","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"2026042311214051600_bib98","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/ajh.27648","article-title":"Donor age matters for haploidentical HCT patients even after adjusting for HLA factors: a machine learning approach","volume":"100","author":"Mehta","year":"2025","journal-title":"Am J Hematol"},{"issue":"4","key":"2026042311214051600_bib42","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/ajh.26834","article-title":"Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia","volume":"98","author":"Guru Murthy","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"2026042311214051600_bib43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12967-017-1277-6","article-title":"Erythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC","volume":"15","author":"Kim-Wanner","year":"2017","journal-title":"J Transl Med"},{"key":"2026042311214051600_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/aob-24-19","article-title":"Optimizing total nucleated cell yield in bone marrow harvests for hematopoietic stem cell transplantation","volume":"9","author":"Rennert","year":"2024","journal-title":"Ann Blood"},{"issue":"5","key":"2026042311214051600_bib99","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/trf.16374","article-title":"The impact of donor total estimated blood volume on nucleated cell yield in bone marrow harvests for hematopoietic stem cell transplantation","volume":"61","author":"Rennert","year":"2021","journal-title":"Transfusion (Paris)"},{"issue":"1","key":"2026042311214051600_bib44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"25","key":"2026042311214051600_bib45","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2026042311214051600_bib46","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2026042311214051600_bib47","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ajh.27662","article-title":"Impact of donor age and donor cytomegalovirus serostatus on outcomes after related donor allogeneic hematopoietic stem cell transplantation","volume":"100","author":"Mehta","year":"2025","journal-title":"Am J Hematol"},{"issue":"23","key":"2026042311214051600_bib48","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2026042311214051600_bib49","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3324\/haematol.2016.147645","article-title":"Donor and recipient sex in allogeneic stem cell transplantation: what really matters","volume":"101","author":"Kim","year":"2016","journal-title":"Haematologica"},{"issue":"16","key":"2026042311214051600_bib52","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1182\/bloodadvances.2023010369","article-title":"Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy","volume":"7","author":"Nawas","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2026042311214051600_bib53","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/bloodadvances.2023012385","article-title":"Racial\/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation","volume":"8","author":"Fingrut","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2026042311214051600_bib54","first-page":"345.e1","article-title":"Search summary score: a global measure to predict matched unrelated stem cell donor availability","volume":"32","author":"Fingerson","year":"2026","journal-title":"Transpl Cell Ther"},{"key":"2026042311214051600_bib55","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.16.24313494","article-title":"Access to allogeneic cell transplantation based on donor search prognosis: an interventional trial","author":"Dehn","year":"16  2024","journal-title":"medRxiv"},{"issue":"31","key":"2026042311214051600_bib56","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO-25-00206","article-title":"Primary results from blood and marrow transplant clinical trials network 1702: clinical transplant-related long-term outcomes of alternative donor allogeneic transplantation","volume":"43","author":"Lee","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026042311214051600_bib57","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"2026042311214051600_bib58","first-page":"1155","article-title":"Allogeneic hematopoietic cell transplantation for the treatment of severe aplastic anemia: evidence-based guidelines from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Iftikhar","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2026042311214051600_bib59","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41409-018-0334-y","article-title":"Donor-specific anti-HLA antibodies in unrelated hematopoietic cell transplantation for non-malignant disorders","volume":"54","author":"Woolfrey","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2026042311214051600_bib60","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","article-title":"One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors","volume":"107","author":"Niederwieser","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"2026042311214051600_bib61","first-page":"809","article-title":"Conducting hematopoietic stem cell transplantation in low and middle income countries","volume":"27","author":"Ruiz-Arg\u00fcelles","year":"2022","journal-title":"Hematol Amst Neth"},{"issue":"12","key":"2026042311214051600_bib62","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.bbmt.2015.08.009","article-title":"Suitability criteria for adult related donors: a consensus statement from the worldwide network for Blood and Marrow Transplantation Standing Committee on donor issues","volume":"21","author":"Worel","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7913","key":"2026042311214051600_bib63","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-04786-y","article-title":"Clonal dynamics of haematopoiesis across the human lifespan","volume":"606","author":"Mitchell","year":"2022","journal-title":"Nature"},{"issue":"9","key":"2026042311214051600_bib64","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/s41375-024-02359-8","article-title":"Older MRD vs. younger MUD in patients older than 50 years with AML in remission using post-transplant cyclophosphamide","volume":"38","author":"Piemontese","year":"2024","journal-title":"Leukemia"},{"issue":"11","key":"2026042311214051600_bib65","first-page":"697.e1-697.e10","article-title":"Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome","volume":"29","author":"Pereira","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"9","key":"2026042311214051600_bib66","first-page":"578.e1-578.e9","article-title":"Impact of donor age on allogeneic hematopoietic cell transplantation outcomes in older adults with acute myeloid leukemia","volume":"29","author":"Abid","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"20","key":"2026042311214051600_bib67","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1182\/bloodadvances.2024015582","article-title":"Older matched sibling donor vs young haplo-identical donor for elderly patients with acute myeloid leukemia","volume":"9","author":"Poire","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"2026042311214051600_bib68","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.2021011281","article-title":"HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis","volume":"138","author":"Gooptu","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2026042311214051600_bib70","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell\u2013replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026042311214051600_bib71","first-page":"395.e1-395.e11","article-title":"Haploidentical versus matched unrelated versus matched sibling donor hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Mehta","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2026042311214051600_bib72","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","article-title":"Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT","volume":"13","author":"Sanz","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2026042311214051600_bib73","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-021-01094-2","article-title":"Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT","volume":"14","author":"Sanz","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"15","key":"2026042311214051600_bib76","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/bloodadvances.2025016236","article-title":"Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis","volume":"9","author":"Aljawai","year":"2025","journal-title":"Blood Adv"},{"issue":"12","key":"2026042311214051600_bib78","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.bbmt.2020.07.030","article-title":"Guidelines for cord blood unit selection","volume":"26","author":"Politikos","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"14","key":"2026042311214051600_bib79","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.19.02408","article-title":"Nonmyeloablative alternative donor transplantation for Hodgkin and non-Hodgkin lymphoma: from the LWP-EBMT, Eurocord, and CIBMTR","volume":"38","author":"Fatobene","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026042311214051600_bib80","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/hematology.2022000327","article-title":"In 2022, which is preferred: haploidentical or cord transplant?","volume":"2022","author":"Nagler","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"2026042311214051600_bib82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/asheducation-2017.1.645","article-title":"HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities","volume":"2017","author":"Gladstone","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"12","key":"2026042311214051600_bib83","first-page":"1139","article-title":"ASTCT consensus recommendations on testing and treatment of patients with donor-specific anti-HLA antibodies","volume":"30","author":"Kongtim","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"2026042311214051600_bib84","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/TP.0b013e3181b9d710","article-title":"High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem cell transplantation","volume":"88","author":"Ciurea","year":"2009","journal-title":"Transplantation"},{"issue":"8","key":"2026042311214051600_bib85","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.bbmt.2015.05.001","article-title":"Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation","volume":"21","author":"Ciurea","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"2026042311214051600_bib86","first-page":"493.e1-493.e10","article-title":"Donor-specific HLA antibodies are associated with graft failure and delayed hematologic recovery after unrelated donor hematopoietic cell transplantation","volume":"29","author":"Lima","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"20","key":"2026042311214051600_bib87","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1182\/bloodadvances.2021004862","article-title":"Treatment of allosensitized patients receiving allogeneic transplantation","volume":"5","author":"Ciurea","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2026042311214051600_bib88","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/ajt.12048","article-title":"Frequency and determinants of pregnancy-induced child-specific sensitization","volume":"13","author":"H\u00f6nger","year":"2013","journal-title":"Am J Transpl"},{"issue":"suppl 1","key":"2026042311214051600_bib100","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood-2025-2434","article-title":"Impact of HLA alloimmunization on availability of HLA well matched and mismatched unrelated allogeneic hematopoietic cell donors for transplantation [abstract]","volume":"46","author":"Shaffer","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026042311214051600_bib89","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/bloodadvances.2023011814","article-title":"Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7\/8-matched unrelated donor","volume":"8","author":"Fingerson","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"2026042311214051600_bib90","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation","volume":"53","author":"Ciurea","year":"2018","journal-title":"Bone Marrow Transpl"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/17\/1903\/2514376\/blood_bld-2025-030823-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/17\/1903\/2514376\/blood_bld-2025-030823-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:22:01Z","timestamp":1776957721000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/17\/1903\/566861\/How-I-select-hematopoietic-cell-donors-in-the-era"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":100,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030823","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,23]]},"published":{"date-parts":[[2026,4,23]]}}}